A5019637171- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Urticaria and Related Conditions
- Psoriasis: Treatment and Pathogenesis
- Contact Dermatitis and Allergies
- Autoimmune Bullous Skin Diseases
- Body Composition Measurement Techniques
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Thermoregulation and physiological responses
- Skin Diseases and Diabetes
- Adrenal Hormones and Disorders
- Dermatological and Skeletal Disorders
- Fungal Infections and Studies
- Psychosomatic Disorders and Their Treatments
- Cutaneous lymphoproliferative disorders research
- Hidradenitis Suppurativa and Treatments
- Poxvirus research and outbreaks
- IL-33, ST2, and ILC Pathways
- Inflammatory Myopathies and Dermatomyositis
- Cannabis and Cannabinoid Research
- Genetics and Physical Performance
- Electrical and Bioimpedance Tomography
- Microscopic Colitis
Università Cattolica del Sacro Cuore
1985-2025
Agostino Gemelli University Polyclinic
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
University of Florence
2015-2022
University of Rome Tor Vergata
2021
University of Molise
2021
Policlinico Tor Vergata
2021
RELX Group (United States)
2020
University of Reggio Calabria
1988
University of Messina
1984
Janus kinase (JAK) inhibitors, including upadacitinib, have been recently approved for the treatment of moderate-severe atopic dermatitis (AD) and real-world data on upadacitinib effectiveness safety are limited. This interim analysis aimed to assess throughout 48 weeks observation in a adult AD population. prospective study collected patients affected by moderate-to-severe treated with at dosage either 15 mg or 30 daily based physician decision. Upadacitinib was prescribed context national...
There is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy in large populations required.
The immunopathogenesis of HS is partially understood and exhibits features an autoinflammatory disease; it associated with the potential involvement B cells contribution Th1 or Th17 cell subsets. Recently, pathogenic role both innate immunity IL-1 family cytokines in has been deeply investigated. Several agents targeting pathway at different levels are currently available under investigation for treatment HS. still characterized by unmet clinical needs represents expanding field current...
The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been defined clinical trials, but no real-world data are currently available. We aimed to assess the effectiveness a AD patient cohort that mostly included patients who failed available systemic therapies, including dupilumab.Prospective study collecting on upadacitinib-treated adult completing at least 16 weeks therapy.Forty-three showed rapid marked response with significant reduction all disease severity scores since...
Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 involving 35 Italian dermatology units, was established order to evaluate impact COVID‐19 pandemic on adult AD treated with systemic medications phototherapy. Demographic clinical data were obtained at different timepoints by...
<b><i>Background:</i></b> Dupilumab, a monoclonal antibody inhibiting the signaling pathway of IL-4/IL-13, was shown to be safe and effective in treatment moderate/severe atopic dermatitis (AD) several clinical trials real-life experiences, with only small percentage patients showing resistant or lose disease control. <b><i>Objectives:</i></b> In this study, we investigated effectiveness safety combining dupilumab systemic agents phototherapy...
Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impairs the quality of life. Recent advancements in systemic therapies, such as Janus kinase (JAK) inhibitors, offer very effective new treatment options. However, concerns regarding potential adverse events, including cardiovascular and thromboembolic risk, have emerged from clinical studies call for further real-life investigations. This has highlighted need to establish specific risk categories, tobacco...
The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands genitalia) remains a significant challenge, even with the advent current range biologic therapies. Recently, Upadacitinib, selective inhibitor JAK1 enzyme, has been approved for moderate to severe promising results have observed in AD located areas. aim this multi-center observational study was better characterize effectiveness Upadacitinib areas, using specific clinimetric tools. We enrolled 74 adult...
Background: This study aims to explore the relationship between Health literacy (HL), vaccination behaviors and Vaccination unawareness (VU) by trying understand how HL influences attitudes potential mediation of VU. Methods: Data were collected using HLS-EU-Q16, Attitude Scale Vaccine Unawareness Scale. Results: The results show that 17.3% variance in total VAX-I is explained predictors. Among significant predictors, low VU age positively predicts VAX-I, while adequate negatively VAX-I....
Dupilumab, blocking IL-4 and IL-13 signals, improves atopic dermatitis Quality of Life but might be also associated with the occurrence ocular adverse events (OAEs). The main objective our prospective study was to characterize cytokine chemokine profile in tear fluid dupilumab-treated patients moderate-to- severe identify biomarkers predicting events. Patients moderate-to-severe AD underwent dermatological ophthalmological evaluation at baseline (T0) week 16 or time an eventual (T1). A...
Abstract Adult atopic dermatitis (adult AD) is a systemic inflammatory disorder, whose relationship with immune-allergic and metabolic comorbidities not well established yet. Moreover, treatment of mild-to-moderate severe needs standardization among clinicians. The aim this study was to evaluate the distribution comorbidities, including abnormalities, rhinitis, conjunctivitis, asthma, alopecia sleep disturbance, according severity adult AD, describe treatments most commonly used by Italian...
Objectives The purpose of this study was to analyze the drug survival rate dupilumab up 2 years in a large real-world cohort adult patients affected by moderate/severe atopic dermatitis (AD), and investigate clinical, demographic predictive factors influencing patients' treatment persistence.Material methods This included moderate-to-severe AD treated with for at least 16 weeks who visited 7 dermatologic outpatient clinics Lazio, Italy, from January 2019 until August 2021.Results A total 659...
Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings.This study aimed identify predictive clinical demographic factors affecting patient selection spacing or withdrawal due satisfactory response.This retrospective included adult patients with moderate-to-severe AD treated dupilumab at least 16 weeks....
<b><i>Background:</i></b> Atopic dermatitis (AD) is a chronic inflammatory skin disorder that associated with higher rates of psychological disorders, but limited evidence supported the association alexithymia, psychoaffective dysfunction. <b><i>Objectives:</i></b> This study was aimed to investigate occurrence alexithymia in AD patients, compared healthy subjects. <b><i>Methods:</i></b> cross-sectional assessed severity...
Localization of atopic dermatitis (AD) in exposed areas such as the hands, head, and neck has been considered a negative factor impacting on dupilumab response, although comparison versus unexposed is not currently available.The aim this study to evaluate clinical response depending presence or persistency AD skin manifestations specific body areas.The retrospectively collected demographic data adult patients affected by moderate severe AD. Based anatomical sites involved, 5 subcohorts were...